Table 2.
Markers of CSCs for different malignancies.
| Types of Cancer | Marker Signature of CSCs |
|---|---|
| Hematological malignancy | |
| Acute lymphoid leukemia | CD34+/CD38−/CD19+ (69) |
| Acute myeloid leukemia | CD34+/CD38− (70) |
| NANOG (71) | |
| OCT4 (72) | |
| ALDHA1 (73) | |
| Chronic myeloid leukemia | ALDHA1 (73) |
| CD34+/CD38−/CD26+ (74) | |
| ALDHA1/SOX2/NANOG (32) | |
| Hodgkin lymphoma | CD27+/ALDH+/(CD19+/CD20+) (75) |
| Solid tumors | |
| Breast cancer | OCT4/NANOG/(CD)44+/CD20 (76) |
| LGR5 (77) | |
| CD44/OCT4/NANOG/SOX2 (29) | |
| ALDH1A1 (78) | |
| Colorectal cancer | OCT4/NANOG (79) |
| AGR2/LGR5 (80) | |
| CD133+ (2) | |
| CD133/CD44 (81) | |
| Glioblastoma | CD133+ (82) |
| Hepatocellular cancer | CD133+/EpCAM+ (83) |
| CD90+/CD44 (84) | |
| Lung cancer | CD133+ (85) |
| CD117+ (86) | |
| ALDH+ (87) | |
| OCT4A/CD133/ALDH (88) | |
| CD44+ (89) | |
| SOX2 (90) | |
| Medulloblastoma, melanoma | CD133+ (91) |
| Ovarian cancer | CD44/CD105/CD106 (92) |
| CD133+ (93) | |
| ALDH+/CD133+ (94) | |
| CD44+/CD117+ (95) | |
| Pancreatic cancer | CD44+/CD24+ (96) CD133+/ALDHA1 (97) |
| CD44/OCT4/NANOG/SOX2 (98) | |
| Prostate cancer | CD133/CD44/OCT4/NANOG/SOX2/ABCB1/ABCG2/ABCC1 (99) |